460 related articles for article (PubMed ID: 22691112)
1. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices.
Asakura Y; Nishimura N; Maezawa K; Terajima T; Kizu J; Chohnabayashi N
J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112
[TBL] [Abstract][Full Text] [Related]
2. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.
Halpin DM; Dahl R; Hallmann C; Mueller A; Tashkin D
Int J Chron Obstruct Pulmon Dis; 2015; 10():239-59. PubMed ID: 25709423
[TBL] [Abstract][Full Text] [Related]
3. Tiotropium Respimat inhaler and the risk of death in COPD.
Wise RA; Anzueto A; Cotton D; Dahl R; Devins T; Disse B; Dusser D; Joseph E; Kattenbeck S; Koenen-Bergmann M; Pledger G; Calverley P;
N Engl J Med; 2013 Oct; 369(16):1491-501. PubMed ID: 23992515
[TBL] [Abstract][Full Text] [Related]
4. Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch.
Hanada S; Wada S; Ohno T; Sawaguchi H; Muraki M; Tohda Y
Int J Chron Obstruct Pulmon Dis; 2015; 10():69-77. PubMed ID: 25609941
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?
Dahl R; Kaplan A
BMC Pulm Med; 2016 Oct; 16(1):135. PubMed ID: 27724909
[TBL] [Abstract][Full Text] [Related]
6. Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients.
Ichinose M; Fujimoto T; Fukuchi Y
Respir Med; 2010 Feb; 104(2):228-36. PubMed ID: 19969446
[TBL] [Abstract][Full Text] [Related]
7. Tiotropium Respimat(®) Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease.
Keating GM
Drugs; 2014 Oct; 74(15):1801-16. PubMed ID: 25300412
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C
Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642
[TBL] [Abstract][Full Text] [Related]
9. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R
Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
ZuWallack R; Allen L; Hernandez G; Ting N; Abrahams R
Int J Chron Obstruct Pulmon Dis; 2014; 9():1133-44. PubMed ID: 25342898
[TBL] [Abstract][Full Text] [Related]
11. Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials.
Calverley PM; Könen-Bergmann M; Richard F; Bell S; Hohlfeld JM
Adv Ther; 2016 May; 33(5):786-93. PubMed ID: 27084728
[TBL] [Abstract][Full Text] [Related]
12. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD.
Verhamme KM; Afonso A; Romio S; Stricker BC; Brusselle GG; Sturkenboom MC
Eur Respir J; 2013 Sep; 42(3):606-15. PubMed ID: 23520322
[TBL] [Abstract][Full Text] [Related]
13. Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat® Soft Mist™ Inhaler in COPD.
Hodder R; Pavia D; Lee A; Bateman E
Int J Chron Obstruct Pulmon Dis; 2011; 6():245-51. PubMed ID: 21814460
[TBL] [Abstract][Full Text] [Related]
14. Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: are they equivalent?
Mathioudakis AG; Chatzimavridou-Grigoriadou V; Evangelopoulou E; Mathioudakis GA; Siafakas NM
Pulm Pharmacol Ther; 2014 Aug; 28(2):91-7. PubMed ID: 24846455
[TBL] [Abstract][Full Text] [Related]
15. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
Caillaud D; Le Merre C; Martinat Y; Aguilaniu B; Pavia D
Int J Chron Obstruct Pulmon Dis; 2007; 2(4):559-65. PubMed ID: 18268929
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial.
Dahl R; Calverley PM; Anzueto A; Metzdorf N; Fowler A; Mueller A; Wise R; Dusser D
BMJ Open; 2015 Dec; 5(12):e009015. PubMed ID: 26715479
[TBL] [Abstract][Full Text] [Related]
17. Tiotropium versus placebo for chronic obstructive pulmonary disease.
Karner C; Chong J; Poole P
Cochrane Database Syst Rev; 2012 Jul; (7):CD009285. PubMed ID: 22786525
[TBL] [Abstract][Full Text] [Related]
18. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.
Voshaar T; Lapidus R; Maleki-Yazdi R; Timmer W; Rubin E; Lowe L; Bateman E
Respir Med; 2008 Jan; 102(1):32-41. PubMed ID: 17996436
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the efficacy and safety of tiotropium bromide (5 µg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease.
Tang Y; Massey D; Zhong NS
Chin Med J (Engl); 2013; 126(19):3603-7. PubMed ID: 24112149
[TBL] [Abstract][Full Text] [Related]
20. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]